Screening for fragile X syndrome: Information needs for health planners

Journal of Medical Screening

Volumn 4, Issue 2, 1997, Pages 60-94

  Murray, Jenni ^a   Cuckle, Howard ^a   Taylor, Graham ^a   Hewison, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X SYNDROME; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; PHENOTYPE; REVIEW;

EID: 0031395376     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1177/096914139700400204     Document Type: Review

References (301)

1. Partington MW, Robinson H, Laing S, Turner G. Mortality in the fragile X syndrome: preliminary data. Am J Med Genet 1992;43:120-3.
2. Simko A, Hornstein L, Soukup S, Bagamery N. Fragile X syndrome: recognition in young children. Pediatrics 1989; 83:547-52.
3. Hagerman RJ. Physical and behavioural phenotype. In: Hagerman RJ, Silverman AC, eds. Fragile X syndrome: diagnosis, treatment and research. Baltimore: Johns Hopkins University Press, 1991:3-69.
4. Partington MW. The fragile X syndrome II: preliminary data on growth and development in males. Am J Med Genet 1984;17:175-94.
5. Sutherland GR, Hecht F. Fragile sites on human chromosomes. New York: Oxford University Press, 1985.
6. Butler MG, Allen GA, Haynes JL, Singh DN, Watson MS, Breg WR. Anthropometric comparison of mentally retarded males with and without the fragile X syndrome. Am J Med Genet 1991;38:260-8.
7. Meryash DL, Cronk CE, Sacks B, Gerald PS. An anthropmetric study of males with the fragile X syndrome. Am J Med Genet 1984;17:159-74.
8. Elston J. Concomintant strabismus. In: Taylor D, ed. Pediatric ophthalmology. Oxford: Blackwell, 1989:613-33.
9. Catalano RA. Down syndrome. Surv Ophthalmol 1990;34: 385.
10. Schinzel A, Largo RH. The fragile X syndrome (Martin-Bell syndrome): clinical and cytogenetic findings in 16 prepubertal boys and in 4 of their families. Helvetic Pediatrica Acta 1985;40:133-52.
11. Storm RL, Pebenito R, Ferretti C. Ophthlamologic findings in the fragile X syndrome. Arch Ophthalmol 1987;105: 1099-102.
12. Maino DM, Wesson M, Schlange D, Cibis G, Maino JH. Optometric findings in the fragile X syndrome. Optom Vis Sci 1991;68:634-40.
13. King RA, Hagerman RJ, Houghton M. Ocular findings in fragile-X syndrome. Developmental Brain Dysfunction 1995; 8:223-9.
14. Brøndum Nielson K, Tommerup N, Dyggve H, Schou C. Macro-orchidism, mental retardation and the fragile X [letter]. N Engl J Med 1981;305:1348.
15. Brøndum Nielson K, Tommerup N, Dyggve H, Schou C. Macro-orchidism and fragile X mentally retarded males. Hum Genet 1982;61:113-17.
16. Davids JR, Hagerman RJ, Eilert RE. Orthopedic aspects of fragile-x syndrome. J Bone Joint Surg [Am] 1990;72:889-96.
17. Hagerman RJ. Fragile X syndrome. Curr Probl Pediatr 1987; 17:621-74.
18. Simpson NE. Dermatoglyphic indices of males with the fragile X syndrome and of the female heterozygotes. Am J Med Genet 1986;23:171-8.
19. de Vries BBA, Robinson H, Stolte-Dijkstra I, et al. General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 mutation. J Med Genet 1995;32:764-9.
20. Loesch DZ, Huggins RM, Hoang NH. Growth in stature in fragile-X families - a mixed longitudinal-study. Am J Med Genet 1995;58:249-56.
21. Loesch DZ, Lafranchi M, Scott D. Anthropometry in Martin-Bell syndrome. Am J Med Genet 1988;30:149-64.
22. Loehr JP, Synhorst DP, Wolfe RR, Hagerman RJ. Aortic root dilatation and mitral-valve prolapse in the fragile-X syndrome. Am J Med Genet 1986;23:189-94.
23. Sreeram N, Wren C, Bhate M, Robertson P, Hunter S. Cardiac abnormalities in the fragile X-syndrome. Br Heart J 1989;61:289-91.
24. Brondum Nielsen K, Tommerup N, Friis B, Hjelt K, Hippe E. Diagnosis of the fragile X syndrome (Martin-Bell syndrome): clinical findings in 27 males with the fragile site at Xq28. Journal of Mental Deficiency Research 1983;27: 211-22.
25. Musumeci SA, Ferri R, Colognola M, Neir G, Sanfilippo S, Bergonzi P. Prevalence of a novel epileptongenic EGG pattern in the Martin-Bell syndrome. Am J Med Genet 1988;30:207-12.
26. Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD. The fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet 1991;38:476-80.
27. Vieregge P, Froster-Iskenius U. Clinico-neurological investigations in the fraX form of mental retardation. J Neurol 1989;236:85-92.
28. Maes B, Fryns JP, Van Walleghem M, Van den Berghe H. Cognitive functioning and information processing of adult mentally retarded men with fragile-X syndrome. Am J Med Genet 1994;50:190-200.
29. Rousseau F, Heitz D, Tarleton J, et al. A multicenter study on genotype-phenorype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases. Am J Hum Genet 1994;55:225-37.
30. Taylor AK, Safanda JF, Fall MZ, et al. Molecular predictors of cognitive involvement in female carriers of fragile X syndrome. JAMA 1994;271:507-14.
31. Fisch GS, Arinami T, Froster-Iskenius U, et al. Relationship between age and IQ among fragile X males: a multicenter study. Am J Med Genet 1991;38:481-7.
32. Dykens EM, Hodapp RM, Ort S, Finucane B, Shapiro LR, Leckman JF. The trajectory of cognitive development in males with fragile X syndrome. J Am Acad Child Adolesc Psychiatry 1989;28:422-6.
33. Hagerman RJ, Schreiner RA, Kemper MB, Wittenberger MD, Zahn B, Habicht K. Longitudinal IQ changes in fragile X males. Am J Med Genet 1989;33:513-18.
34. Lachiewicz AM, Gullion CM, Spiridigloizzi GA, Aylsworth AS. Declining IQs of young males with the fragile X syndrome. Am J Ment Retard 1987;92:272-8.
35. Hay DA. Does IQ decline with age in fragile-X? A methodological critique. Am J Med Genet 1994;51:358-63.
36. Fisch GS. What is associated with the fragile X syndrome? [review]. Am J Med Genet 1993;48:112-21.
37. Einfeld S, Hall S. Behavior phenotype of the fragile X syndrome. Am J Med Genet 1992;43:56-60.
38. Freund LS, Reiss AL. Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet 1991;38:542-7.
39. Miezejeski CM, Jenkins EC, Hill AL, Wisniewski K, French JH, Brown WT. A profile of cognitive deficit in females from fragile X families. Neuropsychologia 1986;24:405-9.
40. Sudhalter V, Cohen IL, Silverman W, Wolf-Schein EG. Conversational analyses of males with fragile X, Down syndrome and autism: comparison of the evergence of deviant language. Am J Ment Retard 1990;94:431-41.
41. Sudhalter V, Maranion M, Brooks P. Expressive semantic deficit in the productive language of males with fragile X syndrome. Am J Med Genet 1992;43:65-71.
42. Kemper MB, Hagerman RJ, Aktshul-Stark D. Cognitive profiles of boys with the fragile X syndrome. Am J Med Genet 1988;30:191-200.
43. Hagerman RJ, Jackson AW, Levitas A, Rimland B, Braden M. An analysis of autism in fifty males with fragile X syndrome. Am J Med Genet 1986;23:359-74.
44. Wolff PH, Gardner J, Paccia J, Lappen J. The greeting behaviour of fragile X males. Am J Ment Retard 1989;93:406-11.
45. Brown WT, Friedman E, Jenkins EC, et al. Association of fragile X syndrome with autism [letter]. Lancet. 1982;i: 100.
46. Meryash DL, Szymanski LS, Gerald PS. Infantile autism associated with the fragile-X syndrome. J Autism Dev Disord 1982;12:295-301.
47. Levitas A, Hagerman RJ, Braden M, Rimland B, McBogg P, Matus I. Autism and the fragile X syndrome. J Dev Behav Pediatr 1983;4:151-8.
48. Einfeld S, Molony H, Hall W. Autism is not associated with the fragile X syndrome. Am J Med Genet 1989;34:187-93.
49. Fisch GS. Is autism associated with the fragile X syndrome? Am J Med Genet 1992;43:47-55.
50. Einfeld SL, Tonge BJ, Florio T. Behavioural and emotional disturbance in fragile X syndrome. Am J Med Genet 1994; 51:386-91.
51. Schapiro MB, Murphy DGM, Hagerman RJ, et al. Adult fragile X syndrome: neuropsychology, brain anatomy and metabolism. Am J Med Genet 1995;60:480-93.
52. Cohen IL, Vietze PM, Sudhulter V, Jenkins EC, Brown WT. Parent-child dyadic gaze patterns in fragile X males and in non-fragile X males with autistic disorder. J Child Psychol Psychiatry 1989;30:845-56.
53. Sudhalter V, Scarborough HS, Cohen IL. Syntactic delay and pragmatic deviance in the language of fragile X males. AmJ Med Genet 1991;38:493-7.
54. Largo RH, Schinzel A. Developmental and behavioural disturbances in 13 boys with fragile X syndrome. Eur J Pediatr 1985;143:269-75.
55. Fryns JP, Kleczkowska A, Kubien E, Van den Berghe H. Cytogenetic findings in moderate and severe mental retardation. A study of an institutionalized population of 1991 patients. Acta Paediatr Scand 1984;Ss313:1-23.
56. Finnelli PF, Pueschel SM, Padre-Mendoza T, et al. Neurological findings in patients with the fragile X syndrome. J Neurol Neurosurg Psychiatry 1985;48:150-3.
57. Einfeld S, Hall W, Levy F. Hyperactivity and the fragile X syndrome. J Abnorm Child Psychol 1991;19:253-62.
58. Turk J. The psychiatric, psychological and behavioural functioning of a British sample of boys with the fragile X syndrome. University of London, 1995. (MD thesis.)
59. Hagerman RJ, Kemper M, Hudson M. Learning disabilities and attentional problems in boys with the fragile X syndrome. Am J Dis Child 1985;139:674-8.
60. Lejeune J. Is the fragile X syndrome amenable to treatment? Lancet 1982;i:273-4.
61. Brown WT, Jenkins EC, Friedman E, et al. Folic acid therapy in the fragile X syndrome. Am J Med Genet 1984; 17:289-97.
62. Brown WT, Cohen IL, Fisch GS, et al. High dose folic acid treatment of fragile (X) males. Am J Med Genet 1986;23:263-71.
63. Gillberg C, Wahlstrom J, Johansson R, Tornblom M, Albertsson-Wikland K. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol 1986;28:624-7.
64. Fisch GS, Cohen IL, Gross AC, Jenkins V, Jenkins EC, Brown WT. Folic acid treatment of fragile X males: a further study. Am J Med Genet 1988;30:393-9.
65. Strom CM, Brusca RM, Pizzi WJ. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet 1992;44:676-82.
66. Turk J. The fragile X syndrome:recent developments. Current Opinion in Psychology 1992;2:677-82.
67. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 1988;30:377-92.
68. Hagerman RJ, Riddle JE, Roberts LS, Breese K, Fulton M. Survey of the efficacy of clonidine in fragile-X syndrome. Developmental Brain Dysfunction 1995;8:336-44.
69. Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry 1943;6:154-7.
70. Lubs HA. A marker X-chromosome. Am J Hum Genet 1969;21:231-14.
71. Sutherland GR. Fragile sites on human chromsomes: demonstration of their dependence on the type of tissue culture medium. Science 1977;197:136-18.
72. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-14.
73. Sherman SL, Morton NE, Jacobs PA, Turner G. The marker (X) syndrome: a cytogenetic and genetic analysis. Ann Hum Genet 1984;48:21-37.
74. Webb T. Delayed replication of Xq27 in individuals with the fragile X syndrome. Am J Med Genet 1992;43:1057-62.
75. Hansen RS, Canfield TK, Lamb MM, Gartler SM, Laird CD. Association of fragile X syndrome with delayed replication of the FMR1 gene. Cell 1993;73:1403-9.
76. Sutherland GR, Ledbetter DH. Report of the committe on cytogenetic markers. Cytogenet Cell Genet 1989;15:452.
77. Sutherland GR, Baker E. Characterisation of a new rare fragile site easily confused with the fragile X. Hum Mol Genet 1992;1:111-13.
78. Knight SJ, Flannery AV, Hirst MC, et al. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 1993;74:127-34.
79. Knight SJL, Voelckel MA, Hirst MC, Flannery AV, Moncla A, Davies KE. Triplet repeat expansion at the FRAXE locus and X-linked mild mental handicap. Am J Hum Genet 1994;55:81-6
80. Hamel BC, Smits AP, de Graaff E, et al. Segregation of FRAXE in a large family: clinical, psychometric, cytogenetic, and molecular data. Am J Hum Genet 1994;55:923-31.
81. Mulley JC, Yu S, Loesch DZ, et al. FRAXE and mental retardation. J Med Genet 1995;32:162-9.
82. Bullock S, Felix CA, Butterworth MA, Stevenson K, Williams D. The use of molecular DNA testing to distinguish between mutations at the fragile X-A and -E sites. J Med Genet 1995;32:154.
83. Murray A, Youings S, Dennis N, et al. Population screening at the FRAXA and FRAXE loci: molecular analyses of boys with learning difficulties and their mothers. Hum Mol Genet 1996;5:727-35.
84. Sutherland GR, Baker E. The common fragile site in band Xq27 of the human X chromosome is not coincident with the fragile X. Clin Genet 1990;37:167-72.
85. Hirst MC, Barnicoat A, Flynn G. The identification of a third fragile site, FRAXF in Xq27-28 distal to both FRAXA and FRAXE. Hum Mol Genet 1993;2:197-200.
86. Parrish JE, Oostra BA, Verkerk AJ, et al. Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. Nat Genet 1994;8:229-35.
87. Soudek D, Partington MW, Lawson JS. The fragile X syndrome I: familial variation in the proportion of lymphocytes with the fragile site in males. Am J Med Genet 1984;17:241-52.
88. Hecht F, Fryns JP, Vlietinck RF, van den Berghe H. Genetic control over fragile X chromosome expression. Clin Genet 1986;29:191-5.
89. Fisch GS, Silverman W, Jenkins EC. Genetic and other factors that contribute to variability in cytogenetic expression in fragile X males. Am J Med Genet 1991;38:404-7.
90. Jacky PB, Ahuja YR, Anyane-Yeboa K, et al. Guidelines for the preparation and analysis of the fragile X chromosome in lymphocytes. Am J Med Genet 1991;38:400-3.
91. Glover TW. FUdR induction of the X chromosome fragile site: evidence for the mechanism of folic acid and thymidine inhibition. Am J Hum Genet 1981;33:234-42.
92. Cantu ES, Nussbaum RL, Airhart SD, Ledbetter DH. Fragile (X) expression induced by FUdR is transient and inversely related to levels of thymidylate synthase activity. Am J Hum Genet 1985;37:947-55.
93. Sutherland GR, Baker E, Fratini A. Excess thymidine induces folate sensitive fragile sites. Am J Med Genet 1985; 22:433-13.
94. Krawczun MS, Lele KP, Jenkins EC, Brown WT. Fragile X expression increased by low cell-culture density. Am J Med Genet 1986;23:467-73.
95. Gustavson KH, Dahlbom K, Flood A, Holmgrem, G, Blomquist HK, Sanner G. Effect of folic acid treatment in the fragile X syndrome. Clin Genet 1985;27;463-7.
96. Rousseau F, Heitz D, Oberlé I, Mandel JL. Selection in blood cells from female carriers of the fragile X syndrome: inverse correlation between age and proportion of active X chromosomes carrying the full mutation. J Med Genet 1991;28:830-6.
97. Brøndum Nielson K, Tommerup N. Cytogenetic investigation in mentally retarded and normal males from 14 families with the fragile site at Xq28: results of folic acid treat-ment on fra(X) expression. Hum Genet 1984;66:225-9.
98. Richards RI, Sutherland GR. Heritable unstable DNA sequences [news]. Nat Genet 1992;1:7-9.
99. Kremer EJ, Pritchard M, Lynch M, et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 1991;252:1711-14.
100. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991;67:1047-58.
101. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-99.
102. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
103. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslatedregion of the gene. Science 1992;255:1253-5.
104. Fu YH, Pizzuti A, Fenwick RG, et al. An unstable triplet repeat in a gene related to myotonic dystrophy. Science 1992;255:1256-8.
105. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
106. Orr HT, Chung M-Y, Banfi S, et al. Expansion of an unstable CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993;4:221-6.
107. Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994;6:9-13.
108. Nagafuchi S, Yanagisawa H, Sato K, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12. Nat Genet 1994;6:14-18.
109. Eichler EE, Richarrds S, Gibbs A, Nelson DL. Fine structure of the human FMR1 gene. Hum Mol Genet 1993;2:1147-53.
110. Yu S, Mulley J, Loesch D, et al. Fragile-X syndrome: unique genetics of the heritable unstable element. Am J Hum Genet 1992;50:968-80.
111. Caskey CT, Pizzuti A, Fu Y-H, Fenwick RG, Nelson DL. Triplet repeat mutations in human disease. Science 1992;256:784-9.
112. Ashley CT, Sutcliffe JS, Kunst CB, et al. Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet 1993; 4:244-51.
113. Bell MV, Hirst MC, Nakahori Y, et al. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 1991;64:861-6.
114. Oberlé I, Rousseau F, Heitz D, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991;252:1097-102.
115. Verheij C, Bakker CE, de Graaff E, et al. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993;363:722-4.
116. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 1993;4:335-40.
117. Bachner D, Manca A, Steinbach P, et al. Enhanced expression of the murine FMR1 gene during germ cell proliferation suggests a special function in both the male and the female gonad. Hum Mol Genet 1993;2:2043-50.
118. Hinds HL, Ashley CT, Sutcliffe JS, et al. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet 1993;3:36-43.
119. Verheij C, de Graaff E, Bakker CE, et al. Characterisation of FMR1 proteins isolated from different tissues. Hum Mol Genet 1995;4:895-901.
120. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 1993;74:291-8.
121. Ashley CT Jr, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective binding. Science 1993;262:563-6.
122. Feng Y, Lakkis L, Devys D, Warren ST. Quantitative comparison of FMR1 gene expression in normal and premutation alleles. Am J Hum Genet 1995;56:106-13.
123. Khandjian EW, Corbin F, Woerly S, Rousseau F. The fragile X mental retardation protein is associated with ribosomes. Nat Genet 1996;12:91-3.
124. Gedeon AK, Baker E, Robinson H, et al. Fragile X syndrome without CCG amplification has an FMR1 deletion. Nat Genet 1992;1:341-1.
125. Wöhrle D, Kotzot D, Hirst MC, et al. A microdeletion of less than 250 kb, including the proximal part of the FMR-1 gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. Am J Hum Genet 1992;51: 299-306.
126. Meijer H, de Graaff E, Merckx DM, et al. A deletion of 1.6 kb proximal to the CGG repeat of the FMR1 gene causes the clinical phenotype of the fragile X syndrome. Hum Mol Genet 1994;3:615-20.
127. Snow K, Doud LK, Hagerman R, Pergolizzi RG, Erster SH, Thibodeau SN. Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet 1993;53:1217-28.
128. Eichler EE, Holden JJA, Popovich BW, et al. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet 1994;8:88-94.
129. Hirst MC, Grewal PK, Davies KE. Precursor arrays for triplet repeat expansion at the fragile X locus. Hum Mol Genet 1994;3:1553-60.
130. Kunst CB, Warren ST. Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell 1994;77:853-61.
131. Snow K, Tester DJ, Kruckeberg KE, Schaid DJ, Thibodeau SN. Sequence analysis of the fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet 1994;3:1543-51.
132. Dawson AJ, Chodirker BN, Chudley AE. Frequency of FMR1 premutations in a consecutive newborn population by PCR screening of Guthrie blood spots. Biochem Mol Med 1995;56:63-9.
133. Eichler EE, Hammond HA, Macpherson JN, Ward PA, Nelson DL. Population survey of the human FMR1 CGG repeat substructure suggests biased polarity for the loss of AGG interruptions. Hum Mol Genet 1995;4:2199-208.
134. Brown WT, Nolin S, Houck G, et al. Prenatal-diagnosis and carrier screening for fragile X by PCR. Am J Med Genet 1996;64:191-5.
135. Kunst CB, Zerylnick C, Karickhoff L, et al. FMR1 in global populations. Am J Hum Genet 1996;58:513-22.
136. Brown WT, Houck GE Jr, Jeziorowska A, et al. Rapid fragile X carrier screening and prenatal diagnosis using a non-radioactive PCR test. JAMA 1993;270:1569-75.
137. Arinami T, Asano M, Kobayashi K, Yanagi H, Hamaguchi H. Data on the CGG repeat at the fragile X site in the non-retarded Japanese population and family suggest the presence of a subgroup of normal alleles predisposing to mutate. Hum Genet 1993;92:431-6.
138. Yu S, Pritchard M, Kremer E, et al. Fragile X genotype characterized by an unstable region of DNA. Science 1991; 252:1179-81.
139. Pieretti M Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991;66:817-22.
140. Sutcliffe JS, Nelson DL, Zhang F, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1992;1:397-400.
141. Rousseau F, Heitz D, Biancalana V, et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med 1991;325:1673-81.
142. de Vries BB, Wiegers AM, de Graaff E, et al. Mental status and fragile X expression in relation to FMR-1 gene mutation. Eur J Hum Genet 1993;1:72-9.
143. Hagerman RJ, Hull CE, Safanda JF, et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet 1994;51:298-308.
144. Väisänen ML, Kähkönen M, Leisti J. Diagnosis of fragile X syndrome by direct mutation analysis. Hum Genet 1994;93: 143-7.
145. Nolin SL, Glicksman A, Houck GE Jr, Brown WT, Dobkin CS. Mosaicism in fragile X affected males. Am J Med Genet 1994;51:509-12.
146. van den Ouweland AM, Deelen WH, Kunst CB, et al. Loss of mutation at the FMR1 locus through multiple exchanges between maternal X chromosomes. Hum Mol Genet 1994;3:1823-7.
147. Loesch DZ, Huggins R, Hay DA, Gedeon AK, Mulley JC, Sutherland GR. Genotype-phenotype relationships in fragile X syndrome: a family study. Am J Hum Genet 1993;53: 1064-73.
148. McConkie-Rosell A, Lachiewicz AM, Spiridigliozzi GA, et al. Evidence that methylation of the FMR-1 locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet 1993;53:800-9.
149. Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, Eberhart D, Warren ST. Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995;268:731-4.
150. Reyniers E, Vits L, de Boulle K, et al. The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm. Nat Genet 1993;4:143-6.
151. de Graaff E, Willemsen R, Zhong N, et al. Instability of the CGG repeat and expression of the FMR1 protein in a male fragile-X patient with a lung-tumor. Am J Hum Genet 1995;57:609-18.
152. Mila M, Castell-Vibel S, Sanchez A, Lazaro C, Villa M, Estivill X. Mosaicism for the fragile-X syndrome full mutation and deletions within the CGG repeat of the FMR1 gene. J Med Genet 1996;33:338-40.
153. van den Ouweland AM, de Vries BB, Bakker PL, et al. DNA diagnosis of the fragile X syndrome in a series of 236 mentally retarded subjects and evidence for a reversal of mutation in the FMR-1 gene. Am J Med Genet 1994;51: 482-5.
154. Wöhrle D, Hirst MC, Kennerknecht I, Davies KE, Steinbach P. Genotype mosaicism in fragile X fetal tissues. Hum Genet 1992;89:114-16.
155. Quan F, Zonana J, Gunter K, Peterson KL, Magenis RE, Popovich BW. An atypical case of fragile X syndrome caused by a deletion that includes the FMR1 gene. Am J Hum Genet 1995;56:1042-51.
156. Hart PS, Olson SM, Crandall K, Tarleton J. Fragile-X syndrome resulting from a 400 basepair deletion within the FMR1 gene. Am J Hum Genet 1995;Ss57:1395.
157. Trottier Y, Imbert G, Poustka A, Fryns JP, Mandel JL. Male with typical fragile X phenotype is deleted for part of the FMR1 gene and for about 100 kb of upstream region. Am J Med Genet 1994;51:454-7.
158. de Graaff E, Rouillard P, Willems PJ, Smits AP, Rousseau F, Oostra BA. Hotspot for deletions in the CGG repeat region of FMR1 in fragile X patients. Hum Mol Genet 1995;4:45-9.
159. de Boulle K, Verkerk AJ, Reyniers E, et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 1993;3:31-5.
160. Reiss AL, Kazazian HH Jr, Krebs CM, et al. Frequency and stability of the fragile X premutation. Hum Mol Genet 1994;3:393-8.
161. Smits A, Smeets D, Hamel B, Dreesen J, de Haan A, van Oost B. Prediction of mental status in carriers of the fragile X mutation using CGG repeat length. Am J Med Genet 1994;51:497-500.
162. Steinbach P, Wöhrle D, Tariverdian G, et al. Molecular analysis of mutations in the gene FMR-1 segregating in fragile X families. Hum Genet 1993;92:491-8.
163. Mazzocco MM, Hagerman RJ, Pennington BF. Problem solving limitations among cytogenetically expressing fragile X women. Am J Med Genet 1992;43:78-86.
164. Mazzocco MM, Pennington BF, Hagerman RJ. The neurocognitive phenotype of female carriers of fragile X: additional evidence for specificity. J Dev Behav Pediatr 1993;14:328-35.
165. Puck JM, Stewart CC, Nussbaum RL. Maximum-likelihood analysis of human T-cell X chromosome inactivation patterns: normal women versus carrier of X-linked severe combined immunodeficiency. Am J Hum Genet 1992;50:742-8.
166. Fialkow BJ. Primordial cell pool size and lineage relationships of five human cell types. Ann Hum Genet 1973;37:39-48.
167. Kirchgessner CU, Warren ST, Willard HF. X inactivation of the FMR1 fragile X mental retardation gene. J Med Genet 1995;32:925-9.
168. Watkiss E, Webb T. Comparison of methods for studying X inactivation status in females. J Med Genet 1995;32:151.
169. Reiss AL, Freund LS, Baumgardner TL, Abrams MT, Denckla MB. Contribution of the FMR1 gene mutation to human intellectual dysfunction. Nat Genet 1995;11:331-4.
170. Azofeifa J, Waldherr R, Cremer M. X-chromosome methylation ratios as indicators of chromosomal activity: evidence of intraindividual divergencies among tissues of different embryonal origin. Hum Genet 1996;97:330-3.
171. Fisch GS, Snow K, Thibodeau SN, et al. The fragile X premutation in carriers and its effect on mutation size in offspring. Am J Hum Genet 1995;56:1147-55.
172. Tizzano EF, Baiget M. High proportion of twins in carriers of fragile X syndrome. J Med Genet 1992;29:599.
173. Turner G, Robinson H, Wake S, Martin N. Dizygous twinning and premature menopause in fragile X syndrome. Lancet 1994;344:1500.
174. Schwartz CE, Dean J, Howard-Peebles PN, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994;51:400-2.
175. Hull C, Hagerman RJ. A study of the physical, behavioral, and medical phenotype, including anthropometric measures, of females with fragile X syndrome. Am J Dis Child 1993;147:1236-11.
176. Conway GS, Hettiarachchi S, Murray A, Jacobs PA. Fragile X premutations in familiial premature ovarian failure. Lancet 1995;346:309-10.
177. Reiss AL, Freund L, Abrams MT, Boehm C, Kazazian H. Neurobehavioral effects of the fragile X premutation in adult women: a controlled study. Am J Hum Genet. 1993;52:884-94.
178. Thompson NM, Gulley ML, Rogeness GA, et al. Neurobehavioral characteristics of CGG amplification status in fragile X females. Am J Med Genet 1994;54:378-83.
179. Sobesky WE, Pennington BF, Porter D, Hull CE, Hagerman RJ. Emotional and neurocognitive deficits in fragile X. Am J Med Genet 1994;51:378-85.
180. Steyaert J, Borghgraef M, Fryns JP. Apparently enhanced visual information processing in female fragile X carriers: preliminary findings. Am J Med Genet 1994;51:374-7.
181. von Koskull H, Gahmberg N, Salonen R, Salo A, Peippo M. FRAXA locus in fragile X diagnosis: family studies, prenatal diagnosis, and diagnosis of sporadic cases of mental retardation. Am J Med Genet 1994;51:486-9.
182. Macpherson J, Harvey J, Curtis G, et al. A reinvestigation of thirty three fragile(X) families using probe StB12.3. Am J Med Genet 1992;43:905-12.
183. Mingroni-Netto RC, Fernandes JG, Vianna-Morgante AM. Relationship of expansion of CGG repeats and X-inactivation with expression of fra(X)(q27.3) in heterozygotes. Am J Med Genet 1994;51:443-6.
184. Snow K, Doud L, Hagerman R, et al. Analysis of mutations at the fragile X locus using the DNA probe Ox1.9. Am J Med Genet 1992;43:244-54.
185. Wang Q, Green E, Barnicoat A, et al. Cytogenetic versus DNA diagnosis in routine referrals for fragile X syndrome. Lancet 1993;342:1025-6.
186. Holmgren G, Blomquist H, Drugge U, Gustavson K. Fragile X families in a northern Swedish county - a genealogical study demonstrating apparent paternal transmission from the 18th century. Am J Med Genet 1988;30:673-9.
187. Smits AP, Dreesen JC, Post JG, et al. The fragile X syndrome: no evidence for any recent mutations. J Med Genet 1993;30:94-6.
188. Oudet C, von Koskull H, Nordstrom AM, Peippo M, Mandel JL. Striking founder effect for the fragile X syndrome in Finland. Eur J Hum Genet 1993;1:181-9.
189. Oudet C, Mornet E, Serre JL, et al. Linkage disequilibrium between the fragile X mutation and two closely linked CA repeats suggests that fragile X chromosomes are derived from a small number of founder chromosomes. Am J Hum Genet 1993;52:297-304.
190. Buyle S, Reyniers E, Vits L, et al. Founder effect in a Belgian-Dutch fragile X population. Hum Genet 1993;92: 269-72.
191. Malmgren H, Gustavson KH, Oudet C, Holmgren G, Pettersson U, Dahl N. Strong founder effect for the fragile X syndrome in Sweden. Eur J Hum Genet 1994;2:103-9.
192. Macpherson JN, Bullman H, Youings SA Jacobs PA. Insert size and flanking haplotype in fragile X and normal populations: possible multiple origins for the fragile X mutation. Hum Mol Genet 1994;3:399-105.
193. Richards RI, Kondo I, Holman K, et al. Haplotype analysis at the FRAXA locus in the Japanese population. Am J Med Genet 1994;51:412-16.
194. Haataja R, Väisänen ML, Li M, Ryynänen M, Leisti J. The fragile X syndrome in Finland: demonstration of a founder effect by analysis of microsatellite haplotypes. Hum Genet 1994;94:479-83.
195. Chiurazzi P, Genuardi M, Kozak L, et al. Fragile-X founder chromosomes in Italy - a few initial events and possible explanation for their heterogeneity. Am J Med Genet 1996;64:209-15.
196. Eichler EE, Macpherson JM, Murray A, Jacobs PA, Chakravarti A, Nelson DL. Haplotype and interspersion analysis of the FMR1 CGG repeat identifies 2 different mutational pathways for the origin of the fragile-X syndrome. Hum Mol Genet 1996;5:319-30.
197. Zhong N, Kajanoja E, Smits B, et al. Fragile-X founder effects and new mutations in Finland. Am J Med Genet 1996;64:226-33.
198. Zhong N, Yang WH, Dobkin C, Brown WT. Fragile-X gene instability - anchoring AGGs and linked microsatellites. Am J Hum Genet 1995;57:351-61.
199. Richards RI, Sutherland GR. Simple repeat DNA is not replicated simply. Nat Genet 1994:6;114-16.
200. Thommes P, Hubscher U. Eukaryotic DNA replication. Eur J Biochem 1990;194:699-712.
201. Chen X, Mariappan SV, Catasti P, et al. Hairpins are formed by the single DNA strands of the fragile X triplet repeats: structure and biological implications. Proc Natl Acad Sci USA 1995;92:5199-203.
202. Wöhrle D, Hennig I, Vogel W, Steinbach P. Mitotic stability of fragile X mutations in differentiated cells indicates early post-conceptional trinucleotide repeat expansion. Nat Genet 1993;4:140-2.
203. Malmgren H, Steen-Bondeson ML, Gustavson KH, et al. Methylation and mutation patterns in the fragile X syndrome. Am J Med Genet 1992;43:268-78.
204. Kruyer H, Mila M, Glover G, Carbonell P, Ballesta F, Estivill X. Fragile X syndrome and the (CGG)n mutation: two families with discordant MZ twins. Am J Hum Genet 1994;54:437-42.
205. Kähkönen M, Leisti J, Wilska M, Varonen S. Marker X-associated mental retardation. A study of 150 retarded males. Clin Genet 1983;23:397-404.
206. Froster-Iskenius U, Felsch G, Schirren C, Schwinger E. Screening for fra(X)(q) in a population of mentally retarded males. Hum Genet 1983;63:153-7.
207. Paika IJ, Lai F, McAllister NM, Miller WA. The fragile-X marker survey: preliminary report on the screening of suspected fragile X syndrome patients at the Fernald State School. Am J Hum Genet 1984;36:108S.
208. Arinami T, Kondo I, Nakajima S. Frequency of the fragile X syndrome in Japanese mentally retarded males. Hum Genet 1986;73:309-12.
209. Hofstee Y, Arinami T, Hamaguchi H. Comparison between the cytogenetic test for fragile X and the molecular analysis of the FMR-I gene in Japanese mentally retarded individuals. Am J Med Genet 1994;51:466-70.
210. Primrose DA, El-Matmati R, Boyd E, Gosden C, Newton M. Prevalence of the fragile X syndrome in an institution for the mentally handicapped. Br J Psychiatry 1986;148: 655-7.
211. Hagerman R, Berry R, Jackson AW, Campbell J, Smoth ACM, McGavran L. Institutional screening for the fragile X syndrome. Am J Dis Child 1988;142:1216-21.
212. Neri G, Sanfilippo S, Pavone L, et al. The fragile X in Sicily: an epidemiological survey. Am J Med Genet 1988;30: 665-72.
213. Butler MG, Singh DN. Clinical and cytogenetic survey of institutionalized mentally retarded patients with emphasis on the fragile-X syndrome. J Intellect Disabil Res 1993;37: 131-42.
214. Mazurczak T, Bocian E, Milewski M, et al. Frequency of fra-X-syndrome among institutionalized mentally- retarded males in Poland. Am J Med Genet 1996;64:184-6.
215. Gustavson K, Blomquist H, Holmgren G. Prevalence of the fragile X syndrome in mentally retarded boys in a Swedish county. Am J Med Genet 1986;23:581-7.
216. Kähkönen M, Alitalo T, Airaksinen E, et al. Prevalence of the fragile X syndrome in four birth cohorts of children of school age. Hum Genet 1987;77:85-7.
217. Tranebjaerg L, Hilling S, Jessen J, Lind D, Hansen MS. Prevalence of fra(X) in the county of Funen in Denmark is lower than expected. Am J Med Genet 1994;51:423-7.
218. Jacobs PA, Bullman H, Macpherson J, et al. Population studies of the fragile X: a molecular approach. J Med Genet 1993;30:454-9.
219. Morton JE, Bundey S, Webb TP, MacDonald F, Rindl PM, Bullock S. Fragile X syndrome is less common than previously estimated. J Med Genet 1997;34:1-5.
220. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996;64:196-7.
221. Turner G, Robinson H, Laing S, Purvis-Smith S. Preventative screening for the fragile X syndrome. N Engl J Med 1986;315:607-9.
222. Webb T, Bundey S, Thake A, Todd J. The frequency of the fragile X chromosome among schoolchildren in Coventry. J Med Genet 1986;23:396-9.
223. Turner G, Robinson H, Laing S, et al. Population screening for fragile X. Lancet 1992;339:1210-13.
224. Mooney G, Lange M. Antenatal screening: what constitutes benefit? Soc Sci Med 1993;37:873-8.
225. Roy JC, Johnsen J, Breese K, Hagerman R. Fragile-x syndrome - what is the impact of diagnosis on families. Developmental Brain Dysfunction 1995;8:327-35.
226. Palomaki GE. Population based prenatal screening for the fragile X syndrome. J Med Screen 1994;1:65-72.
227. Brock DJ. Carrier screening for cystic fibrosis [review]. Prenat Diagn 1994;13:1243-52.
228. Laing S, Partington M, Robinson M, Turner G. Clinical screening score for the fragile X (Martin-Bell) syndrome. Am J Med Genet 1991;38:256-9.
229. Hagerman RJ, Amiri K, Cronister A. Fragile X checklist. Am J Med Genet 1991;38:283-7.
230. Butler MG, Mangrum T, Gupta R, Singh DN. A 15-item checklist for screening mentally retarded males for the fragile X syndrome. Clin Genet 1991;39:347-54.
231. Nolin SL, Snider DA, Jenkins EC, et al. Fragile X screening program in New York State. Am J Med Genet 1991;38: 251-5.
232. Gabarron J, Lopez I, Glover G, Carbonell P. Fragile X screening program in a Spanish region. Am J Med Genet 1992;43:333-8.
233. Hirst MC, Nakahori Y, Knight SJ, et al. Genotype prediction in the fragile X syndrome. J Med Genet 1991;28:824-9.
234. Nakahori Y, Knight SJ, Holland J, et al. Molecular heterogeneity of the fragile X syndrome. Nucleic Acids Res 1991;19:4355-9.
235. Mulley JC, Yu S, Gedeon AK, et al. Experience with direct molecular diagnosis of fragile X. J Med Genet 1992;29:368-74.
236. Rousseau F, Heitz D, Biancalana V, Oberlé I, Mandel JL. On some technical aspects of direct DNA diagnosis of the fragile X syndrome. Am J Med Genet 1992;43:197-207.
237. El-Aleem AA, Bohm I, Temtamy S, et al. Direct molecular analysis of the fragile X syndrome in a sample of Egyptian and German patients using non-radioactive PCR and Southern blot followed by chemiluminescent detection. Hum Genet 1995;96:577-84.
238. Pergolizzi RG, Erster SH, Goonewardena P, Brown WT. Detection of full fragile X mutation. Lancet 1992;339:271-2.
239. Erster SH, Brown WT, Goonewardena P, Dobkin CS, Jenkins EC, Pergolizzi RG. Polymerase chain reaction analysis of fragile X mutations. Hum Genet 1992;90:55-61.
240. Nanba E, Kohno Y, Matsuda A, et al. Nonradioactive DNA diagnosis for the fragile-X syndrome in mentally-retarded Japanese males. Brain Dev 1995;7:317-21.
241. Haddad LA, Mingroni-Netto RC, Vianna-Morgante AM, Pena SDJ. A PCR based test suitable for screening for fragile X syndrome among mentally retarded males. Hum Genet 1996;97:808-12.
242. Wang Q, Green E, Bobrow M, Mathew CG. A rapid, non-radioactive screening test for fragile X mutations at the FRAXA and FRAXE loci. J Med Genet 1995;32:170-3.
243. Heitz D, Devys D, Imbert G, Kretz C, Mandel JL. Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation. J Med Genet 1992;29:794-801.
244. Willemsen R, Mohkamsing S, Devries B, et al. Rapid antibody test for fragile-X syndrome. Lancet 1995;345:1147-8.
245. Schalling M, Hudson TJ, Buetow KH, Hpusman DE. Direct detection of novel expanded trinucleotide repeats in the human genome. Nat Genet 1993;4:135-9.
246. Jenkins EC, Brown WT, Duncan CJ, et al. Feasibility of fragile X chromosome prenatal diagnosis demonstrated. Lancet 1981;ii:1292.
247. Shapiro LR, Wilmot PL, Brenholz P, et al. Prenatal diagnosis of fragile X chromosome. Lancet 1982;i:99-100.
248. Jenkins EC, Houck GE, Ding XH, et al. An update on fragile-X prenatal-diagnosis - end of the cytogenetic testing era. Developmental Brain Dysfunction 1995;8:293-301.
249. Sutherland GR, Gedeon A, Kornman L, et al. Prenatal diagnosis of fragile X syndrome by direct detection of the unstable DNA sequence. N Engl J Med 1991;325:1720-2.
250. Iida T, Nakahori Y, Tsutsumi O, Taketani Y, Nakagome Y. The CpG island of the FMR-1 gene is methylated differently among embryonic tissues: implication for prenatal diagnosis. Hum Reprod 1994;9:1471-3.
251. Castellvi-Bel S, Mila M, Soler A, et al. Prenatal-diagnosis of fragile-X syndrome-(CGG)n expansion and methylation of chorionic villus samples. Prenat Diagn 1995;9:801-7.
252. Yamauchi M, Nagata S, Seki N, et al. Prenatal diagnosis of fragile X syndrome by direct detection of the dynamic mutation due to an unstable DNA sequence. Clin Genet 1993;44:169-72.
253. Jenkins EC, Morys I, Henderson J, et al. Fragile X induction systems in CVS cultures: effect on cytogenetic, PCR, and genomic Southern blot DNA analyses of the FMR-1 gene. Am J Med Genet 1994;51:436-42.
254. Devys D, Biancalana V, Rousseau F, Boue J, Mandel JL, Oberlé I. Analysis of full fragile X mutations in fetal tissues and monozygotic twins indicates that abnormal methylation and somatic heterogeneity are established early in development. Am J Med Genet 1992;43:208-16.
255. Strain L, Porteous ME, Gosden CM, Ellis PM, Neilson JP, Bonthron DT. Prenatal diagnosis of fragile X syndrome: management of the male fetus with a premutation. Prenat Diagn 1994;14:469-74.
256. Maddalena A, Hicks BD, Spence WC, Levinson G, Howard-Peebles PN. Prenatal diagnosis in known fragile X carriers. Am J Med Genet 1994;51:490-6.
257. Dreesen JCFM, Geraedts JPM, Dumoulin JCM, Evers JLH, Pieters MHEC. RS46(DXS548) genotyping of reproductive cells: approaching preimplantation testing of the fragile X syndrome. Hum Genet 1995;96:323-9.
258. Howard-Peebles PN, Maddalena A, Black SH, Levinson G, Bick DD, Schulman JD. Fragile X screening in pediatric and obstetrical patients. Developmental Brain Dysfunction 1995;8:408-10.
259. Spence WC, Black SH, Fallon L, et al. Molecular fragile-X screening in normal-populations. Am J Med Genet 1996;64: 181-3.
260. Robinson H, Wake S, Wright F, Laing S, Turner G. Informed choice in fragile-X syndrome and its effects on prevalence. Am J Med Genet 1996;64:198-202.
261. Nolin SL, Snider DA, Jenkins EC, et al. New York State screening program for fragile X syndrome: a progress report. Am J Med Genet 1992;43:328-32.
262. Ryynänen M, Kirkinen P, Mannermaa A, Saarikoski S. Carrier diagnosis of the fragile X syndrome - a challenge in antenatal clinics. Am J Obstet Gynecol 1995;172:1236-9.
263. Grasso M, Perroni L, Colella S, et al. Prenatal diagnosis of 30 fetuses at risk for fragile-X-syndrome. Am J Med Genet 1996;64:187-90.
264. American College of Medical Genetics. Fragile X syndrome: diagnostic and carrier testing. Am J Med Genet 1994;53:380-1.
265. Kaplan G, Kung M, McClure M, Cronister A. Direct mutation analysis of 495 patients for fragile X carrier status/proband diagnosis. Am J Med Genet 1994;51:501-2.
266. Barnicoat A, Docherty Z, Bobrow M. Where have all the fragile X boys gone? Dev Med Child Neurol 1993;35:532-539.
267. Mandel JL, Biancalana V, Boiux JC, Cossee M. Screening for the fragile X syndrome mental retardation syndrome. New Horiz Neonat Screen 1994;1041:261-72.
268. Hagerman RJ, Wilson P, Staley LW, et al. Evaluation of school children at high risk for fragile X syndrome utilizing buccal cell FMR-1 testing. Am J Med Genet 1994;51:474-81.
269. Winter RM. Population genetics implications of the premutation hypothesis for the generation of the fragile X mental. Hum Genet 1987;75:269-71.
270. Sved JA, Laird CD. Population genetic consequences of the fragile X syndrome, based on the X-inactivation imprinting model. Am J Hum Genet 1990;46:443-51.
271. Morton NE, Macpherson JN. Population genetics of the fragile-X syndrome: multiallelic model for the FMR1 locus. Proc Natl Acad Sci USA 1992;89:4215-7.
272. Kolehmainen K. Population genetics of fragile X: a multiple allele model with variable risk of CGG repeat expansion. Am J Med Genet 1994;51:428-35.
273. Ashley AE, Sherman SL. Population dynamics of a meiotic/mitotic expansion model for the fragile X syndrome. Am J Hum Genet 1995;57:1414-25.
274. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan N. Prevalence of carriers of premutation-size alleles of the FMR1 gene and implications for the population-genetics of the fragile-X syndrome. Am J Hum Genet 1995; 57:1006-18.
275. Holden JJA, Chalifoux M, Wing M, et al. Distribution and frequency of FMR1 CGG repeat numbers in the general-population. Developmental Brain Dysfunction 1995; 8:405-7.
276. Rousseau F, Morel ML, Rouillard P, Khandjian EW, Morgan K. Surprisingly low prevalence of FMR1 premutation among males from the general population. The National Fragile X Foundation Newletter, July 1996.
277. Sherman SL, Maddalena A, Howard-Peebles PN, et al. Characteristics of the transmission of the FMR1 gene from carrier females in a prospective sample of conceptuses. Am J Med Genet 1994;51:503-6.
278. Richards RI, Holman K, Friend K, et al. Evidence of founder chromosomes in fragile X syndrome. Nat Genet 1992;1:257-60.
279. Chakravarti A. Fragile X founder effect? [news]. Nat Genet 1992;1:237-8.
280. Cuckle HS, Wald NJ. Principles of screening. In: Wald N, ed. Antenatal and neonatal screening for disease. Oxford: Oxford University Press, 1984:1-22.
281. Wald NJ, Cuckle HS. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol 1989;96:389-96.
282. Cuckle H. Established markers in second trimester maternal serum. Early Hum Dev 1996 Ss47;s27-9.
283. Tabor A, Madsen M, Obel EB, Philip J, Bang J, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;i:1287-92.
284. Canadian Colaborative CVS-Amniocentesis Clinical Trial Group. Multicentre randomised clinical trial of chorionic villus sampling and amniocentesis. Lancet 1989;i:1-6.
285. Rhoads GG, Jackson LG, Schlesselman SA, et al. The safety and efficacy of chorionic villus sampling for early-prenatal diagnosis of cytogenetic abnormalities. N Engl J Med 1989;320:609-17.
286. MRC Working Party on the Evaluation of Chorionic Villus Sampling. Medical Research Council European trial of chorionic villus sampling. Lancet 1991:337:1491-9.
287. Smidt-Jensen S, Permin M, Philip J, et al. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 1992;340: 1237-44.
288. Ammala P, Hilesmaa VK, Liukkonben S, Saisto T, Teramo K, von Koskull H. Randomised trial comparing first-trimester transcervical chorionic villus sampling and second-trimester amniocentesis. Prenat Diagn 1993;13: 919-27.
289. Froster UG, Jackson L. Limb defects and chorionic villus sampling: results from an international registry, 1992-94. Lancet 1996;347:489-94.
290. Ghinidi A, Sepulveda W, Lockwood CJ, Romero R. Complications of fetal blood sampling. Am J Obstet Gynecol 1993;168:1339-44.
291. McConkie-Rosell A, Robinson H, Wake S, Staley LW, Heller K, Cronister A. Dissemination of genetic risk information to relatives in the fragile X syndrome: guidelines for genetic counsellors. Am J Med Genet 1995;59:426-30.
292. Nuffield Council on Bioethics. Genetic screening: ethical issues. London: Nuffield Council, 1993.
293. Lauria DP, Webb MJ, McKenzie P, Hagerman R. The economic impact of the fragile X syndrome on the state of Colorado. In: Hagerman RJ, McKenzie P, eds. Proceedings of International Fragile X Conference 1992; chap 52:393-405.
294. Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 1995;311:1460-3.
295. Cuckle H, Quirke P, Sehmi I, et al. Antenatal screening for cystic fibrosis. BrJ Obstet Gynaecol 1996;103:795-9.
296. Sheldon TA, Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ 1991;302: 1133-6.
297. Shackley P, McGuire A, Boyd PA, et al. An economic appraisal of alternative prenatal screening programmes for Down's syndrome. J Publ Health Med 1993;15:175-84.
298. Piggott M, Wilkinson P, Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). J Med Screen 1994;1:45-9.
299. Thornton J, Lilford, RJ. Decision analysis for medical managers - assessment of screening tests. BMJ 1995;310: 791-4.
300. NHS Central Research and Development Committee. The genetics of common diseases. Leeds: Department of Health, 1995.
301. Department of Trade and Industry. Human genetics: the science and its consequences. London: HMSO, 1996.